Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | TSPO | P30536 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL417466 | 0.96 | L3MBTL1 (0.42) | L3MBTL1PLK1TSPOHIF1AALDH1A1 | |
| SCHEMBL414723 | 0.93 | PLK1 (0.44) | L3MBTL1PLK1ALDH1A1LMNALTB4R2 | |
| SCHEMBL414616 | 0.90 | LMNA (0.43) | L3MBTL1TSPOHIF1AALDH1A1LMNA | |
| SCHEMBL414368 | 0.82 | ALDH1A1 (0.40) | ALDH1A1LMNALTB4R2NPC1RAB9A | |
| SCHEMBL413455 | 0.81 | ACHE (0.54) | LMNA | |
| SCHEMBL419661 | 0.81 | RAB9A (0.43) | ALDH1A1LMNALTB4R2NPC1RAB9A | |
| SCHEMBL414300 | 0.80 | BCHE (0.48) | L3MBTL1ALDH1A1LMNAKDM4ELTB4R2 | |
| SCHEMBL417275 | 0.79 | MLNR (0.44) | L3MBTL1ALDH1A1LTB4R2NPC1RAB9A | |
| SCHEMBL411317 | 0.79 | NPC1 (0.45) | ALDH1A1LTB4R2NPC1RAB9A | |
| SCHEMBL415110 | 0.79 | TDP1 (0.48) | ALDH1A1KDM4ELTB4R2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022054-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | LABORATOIRE BIODIM (FR) | 2012-01-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022054-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | HAVCR2, MAVS, EIF2AK2 | L3MBTL1 3171/4885PLK1 3379/4885TSPO 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.